First Trust Advisors LP raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 113.6% during the 1st quarter, Holdings Channel.com reports. The fund owned 800,900 shares of the biotechnology company’s stock after acquiring an additional 425,939 shares during the period. First Trust Advisors LP’s holdings in BioCryst Pharmaceuticals were worth $7,625,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of BCRX. Dimensional Fund Advisors LP raised its holdings in shares of BioCryst Pharmaceuticals by 119.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,690,651 shares of the biotechnology company’s stock valued at $25,615,000 after purchasing an additional 1,461,799 shares during the last quarter. Swiss National Bank boosted its holdings in shares of BioCryst Pharmaceuticals by 3.6% in the 1st quarter. Swiss National Bank now owns 408,668 shares of the biotechnology company’s stock worth $3,891,000 after buying an additional 14,300 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of BioCryst Pharmaceuticals by 4.9% during the 1st quarter. Bank of New York Mellon Corp now owns 637,658 shares of the biotechnology company’s stock valued at $6,071,000 after acquiring an additional 29,666 shares during the period. IMC Chicago LLC purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $6,010,000. Finally, Hillsdale Investment Management Inc. lifted its position in shares of BioCryst Pharmaceuticals by 14.3% during the 1st quarter. Hillsdale Investment Management Inc. now owns 639,100 shares of the biotechnology company’s stock valued at $6,084,000 after buying an additional 80,000 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Cantor Fitzgerald raised their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research report on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target for the company. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada raised their target price on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.
BioCryst Pharmaceuticals Stock Down 2.8%
Shares of NASDAQ:BCRX opened at $8.98 on Friday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22. The company’s fifty day moving average is $9.30 and its 200 day moving average is $8.63. The stock has a market cap of $2.28 billion, a PE ratio of -5.04 and a beta of 0.55.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.20 earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.58 EPS for the current year.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
Read More
- Five stocks we like better than BioCryst Pharmaceuticals
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
